Breast-saving technique also decreases treatment time

July 22, 2004

NEW YORK CITY - Many women are unnecessarily undergoing mastectomy when there is an effective, breast-saving treatment that can be performed in under a week, according to a leading breast cancer specialist.

Robert R. Kuske, M.D., a radiation oncologist with Arizona Oncology Services, discussed accelerated partial breast irradiation (APBI)--also known as brachytherapy--at a Radiological Society of North America (RSNA) media briefing today in New York City.

According to Dr. Kuske, approximately 80 percent of women diagnosed with breast cancer are candidates for breast conservation therapy, in which the lump is surgically removed and any remaining cancerous cells are destroyed by radiation therapy, leaving the breast intact. Unfortunately, despite 20 years of studies demonstrating no difference in survival rates between women receiving mastectomy or lumpectomy followed by radiation therapy, only 55 percent of women opt for the latter treatment.

Dr. Kuske cites two major reasons breast cancer patients avoid breast-saving radiation treatments: "I believe women choose mastectomy because of the inconvenience of six to seven weeks of conventional external beam radiation therapy (EBRT) and the fear of whole-breast irradiation to uninvolved breast, skin, ribs, lung and the heart."

Dr. Kuske has led three trials investigating brachytherapy, a technique that eliminates those barriers. Brachytherapy involves placing a tiny radioactive seed inside the breast, up against the tissues harboring the breast cancer. Since the radiation is directed to the 1 to 2 centimeters of breast surrounding the lumpectomy site, the rest of the breast and surrounding organs are spared, and the entire radiation treatment takes only four to five days. These trials have shown low toxicity and cancer recurrence rates of only 3 to 4 percent in the breast.

Two brachytherapy methods are currently used to place radiation into the treatment area: interstitial brachytherapy, which involves multiple catheters (thin, hollow plastic tubes) around the surgical excision site, or a single balloon catheter that is inserted and then inflated in the lumpectomy cavity. Compared to EBRT, brachytherapy intensely treats the part of the breast that is at the greatest risk for a recurrence of cancer with minimal radiation exposure to the rest of the breast, heart, lungs and skin.

Women are eligible for breast brachytherapy if their tumor size is 3 centimeters or smaller as long as the cells do not reach the surgical margin. Up to three lymph nodes under the arm may be involved.

"Brachytherapy makes breast conservation therapy more convenient for women located in rural areas and for those who have busy lifestyles or occupations that will not accommodate up to seven weeks of radiation treatment," Dr. Kuske said.

Dr. Kuske is currently serving as a co-principal investigator of an upcoming Phase III clinical trial comparing APBI and EBRT, sponsored by the National Cancer Institute through the National Surgical Adjuvant Breast and Bowel Project and the Radiation Therapy Oncology Group.
-end-
RSNA is an association of more than 35,000 radiologists, radiation oncologists and related scientists committed to promoting excellence in radiology through education and by fostering research, with the ultimate goal of improving patient care. The Society is based in Oak Brook, Ill. (http://www.rsna.org/media)

Radiological Society of North America

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.